VRTX241220C505000
- 0.06
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $535
Vertex Pharmaceuticals Price Target Lowered to $441 From $506 at Bernstein
Express News | Vertex Pharmaceuticals-Established Wholesale Acquisition Cost for Alyftrek in United States of $370,269 on Annual Basis ($28,404 per 28-Day Pack)
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
Express News | Vertex Pharmaceuticals Inc: Alyftrek(™) Is Approved for Patients 6 Years and Older With at Least One Responsive Mutation
Express News | Vertex Pharmaceuticals Inc - Alyftrek Includes Boxed Warning of Drug-Induced Liver Injury & Liver Failure
Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Express News | Vertex Announces US FDA Approval of Alyftrek™, a Once-Daily Next-in-Class Cftr Modulator for the Treatment of Cystic Fibrosis
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
Express News | Vertex Pharmaceuticals Inc - Trikafta Can Cause Serious and Potentially Fatal Liver Injury
Express News | Vertex Announces U.S. FDA Approval for Trikafta (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor) to Include Additional Non-F508Del Trikafta-Responsive Variants
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Cautious Outlook on Vertex Pharmaceuticals Due to Suzetrigine's Uncertain Efficacy in DPN Trials
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
Vertex Pharmaceuticals Faces Uncertainty With Mixed Phase 2 Trial Results
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $441 From $506, Maintains Market Perform Rating
Barclays Adjusts Vertex Pharmaceuticals Price Target to $418 From $509, Maintains Equalweight Rating